Der Kaninchen Polyklonal anti-RELB Antikörper (ABIN362926) detektiert spezifisch RELB in WB.
Dieser Antikörper reagiert spezifisch mit Proben aus Human und Maus.
The antibody detects endogenous level of total RelB protein.
Aufreinigung
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. Specificity/Sensitivity RelB (Ab-573) antibody detects endogenous levels of total RelB protein.
Immunogen
Peptide sequence around AA 550-554 (L-L-S-P-G) derived from Human RelB. Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates.
RELB
Reaktivität: Human
WB, IHC, ELISA
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Western blotting: 1:500-1:1000
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store at -20 °C for long term preservation (recommended). Store at 4 °C for short term use.
Target
RELB
(V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))
Andere Bezeichnung
RelB
Hintergrund
NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49.